146 related articles for article (PubMed ID: 36918265)
1. Comprehensive molecular phenotyping of
Xu C; Huang KK; Law JH; Chua JS; Sheng T; Flores NM; Pizzi MP; Okabe A; Tan ALK; Zhu F; Kumar V; Lu X; Benitez AM; Lian BSX; Ma H; Ho SWT; Ramnarayanan K; Anene-Nzelu CG; Razavi-Mohseni M; Abdul Ghani SAB; Tay ST; Ong X; Lee MH; Guo YA; Ashktorab H; Smoot D; Li S; Skanderup AJ; Beer MA; Foo RSY; Wong JSH; Sanghvi K; Yong WP; Sundar R; Kaneda A; Prabhakar S; Mazur PK; Ajani JA; Yeoh KG; So JB; Tan P;
Gut; 2023 Sep; 72(9):1651-1663. PubMed ID: 36918265
[TBL] [Abstract][Full Text] [Related]
2. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities.
Ho SWT; Sheng T; Xing M; Ooi WF; Xu C; Sundar R; Huang KK; Li Z; Kumar V; Ramnarayanan K; Zhu F; Srivastava S; Isa ZFBA; Anene-Nzelu CG; Razavi-Mohseni M; Shigaki D; Ma H; Tan ALK; Ong X; Lee MH; Tay ST; Guo YA; Huang W; Li S; Beer MA; Foo RSY; Teh M; Skanderup AJ; Teh BT; Tan P
Gut; 2023 Feb; 72(2):226-241. PubMed ID: 35817555
[TBL] [Abstract][Full Text] [Related]
3. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract][Full Text] [Related]
5. Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability.
Liu X; Li Z; Wang Z; Liu F; Zhang L; Ke J; Xu X; Zhang Y; Yuan Y; Wei T; Shan Q; Chen Y; Huang W; Gao J; Wu N; Chen F; Sun L; Qiu Z; Deng Y; Wang X
Cancer Res; 2022 Mar; 82(5):791-804. PubMed ID: 34987057
[TBL] [Abstract][Full Text] [Related]
6. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.
Kase K; Saito M; Nakajima S; Takayanagi D; Saito K; Yamada L; Ashizawa M; Nakano H; Hanayama H; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Shiraishi K; Kohno T; Kono K
Carcinogenesis; 2021 Feb; 42(1):21-30. PubMed ID: 33196828
[TBL] [Abstract][Full Text] [Related]
7. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
8. Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.
Loe AKH; Francis R; Seo J; Du L; Wang Y; Kim JE; Hakim SW; Kim JE; He HH; Guo H; Kim TH
J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33822841
[TBL] [Abstract][Full Text] [Related]
9. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
Gu Y; Zhang P; Wang J; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2023 May; 72(5):1199-1208. PubMed ID: 36369379
[TBL] [Abstract][Full Text] [Related]
10. Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer.
Sheng T; Ho SWT; Ooi WF; Xu C; Xing M; Padmanabhan N; Huang KK; Ma L; Ray M; Guo YA; Sim NL; Anene-Nzelu CG; Chang MM; Razavi-Mohseni M; Beer MA; Foo RSY; Sundar R; Chan YH; Tan ALK; Ong X; Skanderup AJ; White KP; Jha S; Tan P
Genome Med; 2021 Oct; 13(1):158. PubMed ID: 34635154
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
[TBL] [Abstract][Full Text] [Related]
12. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of ARID1A mutations with mRNA levels and protein expression in gastric carcinoma.
Hwang I; Cho Y; Kang SY; Kim DG; Ahn S; Lee J; Kim KM
Pathol Res Pract; 2024 Mar; 255():155063. PubMed ID: 38324965
[TBL] [Abstract][Full Text] [Related]
14. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Bhat SA
Pathol Oncol Res; 2021; 27():1609826. PubMed ID: 34924820
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
[TBL] [Abstract][Full Text] [Related]
16. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.
Wang K; Kan J; Yuen ST; Shi ST; Chu KM; Law S; Chan TL; Kan Z; Chan AS; Tsui WY; Lee SP; Ho SL; Chan AK; Cheng GH; Roberts PC; Rejto PA; Gibson NW; Pocalyko DJ; Mao M; Xu J; Leung SY
Nat Genet; 2011 Oct; 43(12):1219-23. PubMed ID: 22037554
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.
Yan HB; Wang XF; Zhang Q; Tang ZQ; Jiang YH; Fan HZ; Sun YH; Yang PY; Liu F
Carcinogenesis; 2014 Apr; 35(4):867-76. PubMed ID: 24293408
[TBL] [Abstract][Full Text] [Related]
18. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
[TBL] [Abstract][Full Text] [Related]
19. Mapping the genomic diaspora of gastric cancer.
Yeoh KG; Tan P
Nat Rev Cancer; 2022 Feb; 22(2):71-84. PubMed ID: 34702982
[TBL] [Abstract][Full Text] [Related]
20. A CRISPR/Cas9-Engineered
Lo YH; Kolahi KS; Du Y; Chang CY; Krokhotin A; Nair A; Sobba WD; Karlsson K; Jones SJ; Longacre TA; Mah AT; Tercan B; Sockell A; Xu H; Seoane JA; Chen J; Shmulevich I; Weissman JS; Curtis C; Califano A; Fu H; Crabtree GR; Kuo CJ
Cancer Discov; 2021 Jun; 11(6):1562-1581. PubMed ID: 33451982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
